Kenvue Inc. (NYSE:KVUE) Shares Sold by Avanza Fonder AB

Avanza Fonder AB reduced its position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 12.9% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 163,498 shares of the company's stock after selling 24,282 shares during the quarter. Avanza Fonder AB's holdings in Kenvue were worth $3,903,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. SRS Capital Advisors Inc. boosted its position in Kenvue by 67.4% during the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock valued at $30,000 after acquiring an additional 571 shares in the last quarter. Asset Planning Inc bought a new stake in Kenvue during the 4th quarter valued at $42,000. Clarity Asset Management Inc. bought a new stake in Kenvue during the 4th quarter valued at $45,000. SBI Securities Co. Ltd. bought a new stake in Kenvue during the 4th quarter valued at $46,000. Finally, Deseret Mutual Benefit Administrators boosted its position in Kenvue by 29.0% during the 4th quarter. Deseret Mutual Benefit Administrators now owns 2,528 shares of the company's stock valued at $54,000 after acquiring an additional 568 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Stock Up 0.9%

Shares of KVUE stock traded up $0.20 on Thursday, reaching $22.05. 28,056,295 shares of the stock were exchanged, compared to its average volume of 16,395,431. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The business's 50 day moving average price is $23.02 and its 200 day moving average price is $22.54. The company has a market capitalization of $42.31 billion, a price-to-earnings ratio of 41.60, a PEG ratio of 2.62 and a beta of 0.98. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.01. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. The company had revenue of $3.74 billion during the quarter, compared to the consensus estimate of $3.69 billion. During the same quarter in the prior year, the firm posted $0.28 earnings per share. Kenvue's revenue for the quarter was down 3.9% on a year-over-year basis. As a group, sell-side analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th were paid a $0.205 dividend. The ex-dividend date was Wednesday, May 14th. This represents a $0.82 annualized dividend and a yield of 3.72%. Kenvue's dividend payout ratio is presently 149.09%.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on KVUE shares. UBS Group raised their price objective on Kenvue from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Friday, May 9th. Piper Sandler raised their price objective on Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a research report on Monday, February 24th. Redburn Atlantic started coverage on Kenvue in a research report on Thursday, April 10th. They issued a "neutral" rating and a $23.50 price objective for the company. Canaccord Genuity Group raised their price objective on Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a research report on Wednesday, March 5th. Finally, Citigroup raised their price objective on Kenvue from $22.00 to $24.50 and gave the stock a "neutral" rating in a research report on Friday, May 9th. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $25.33.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.